Polatuzumab Vedotin
CAS: 1313206-42-6
Description:
Polatuzumab vedotin is an antibody-drug conjugate (ADC) used in cancer treatment. It combines a monoclonal antibody that targets CD79b, a protein on B cells, with the cytotoxic agent monomethyl auristatin E (MMAE). The antibody binds to CD79b on B-cell malignancies, delivering MMAE directly to the tumor cells, causing cell death. It is primarily used to treat B-cell cancers like relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Key Features:
- CD79b Targeting: The antibody specifically targets CD79b on B cells, enabling direct delivery of MMAE to cancer cells.
- Cytotoxic Agent (MMAE): MMAE works by inhibiting microtubule polymerization, leading to cancer cell death.
- Linker Technology: The stable linker between the antibody and MMAE releases the drug inside cancer cells.
Applications:
- Cancer Treatment: Targets and kills CD79b-positive B-cell malignancies, including DLBCL.
- Targeted Therapy: Delivers MMAE directly to cancer cells, minimizing damage to healthy tissue.
- Monoclonal Antibody Therapy: Provides an effective treatment option for patients with relapsed or refractory B-cell cancers, using a precise, targeted approach.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.